Pulsatile drug delivery system: novel approach to target the different diseases including cancer

As we know malignancy is most familiar as a characterization of cancer, a malignant tumor contrasts with a non-cancerous benign tumor in that a malignancy is not self-limited in its growth, is capable of invading into adjacent tissues, and may be capable of spreading to distant tissues. Malignancy in cancers is characterized by anaplasia, invasiveness, and genome instability, so that cancers, as assessed by whole genome sequencing, frequently have between 10,000 and 100,000 mutations in their entire genomes. Cancers usually show tumor heterogeneity, containing multiple sub clones, frequently have reduced expression of DNA repair enzymes due to epigenetic methylation of DNA repair genes or altered micro RNAs that control DNA repair gene expression.
As we move to pulsatile system it releases the drug completely after defined lag time, system is time and site-specific, thus providing special and temporal drug delivery and increasing bioavailability. Targeting malignancy/ cancer, specific drug at site of action requires the specific drug delivery techniques and pulsatile drug delivery is one of them.
The delivery of drugs specifically to the site without being absorbed first in the upper gastrointestinal (GI) tract allows for a higher concentration of the drug to reach the site with minimal systemic absorption. A drug can be delivered to the site via the oral, or the rectal route, as oral dosage forms are the most preferred delivery route for site-specific delivery due to their convenience these forms also allow for a greater degree of flexibility in their manufacturing, design, improved patient adherence & relatively safe administration.